Titan Pharmaceuticals Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 12 Calls Today's Calls

Call Details Titan Pharmaceuticals Earnings Conference Call (Q1 2008) Mon, May 12, 2008, 10:30 am Eastern Listen to the archived event audio About Titan Pharmaceuticals (AMEX:TTP) Titan Pharmaceuticals, Inc., together with its subsidiaries, operates as a biopharmaceutical company that develops proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, and bone disease. Its products include Probuphine, a Phase III clinical trial product for the treatment of opioid addiction; Iloperidone for the treatment of schizophrenia and related psychotic disorders; and Spheramine, a Phase IIb clinical trial product for the treatment of advanced Parkinson’s disease. The company also holds rights to diiodothyropropionic acid, a proprietary product for the treatment of cardiovascular disease; and gallium maltolate, an oral agent for the treatment of chronic bacterial infections, bone disease, and cancer. It has collaboration with Bayer Schering Pharma AG for the development of Spheramine to treat Parkinson’s disease; and with Vanda Pharmaceuticals, Inc. to develop iloperidone for the treatment of schizophrenia and related psychotic disorders. The company was founded in 1992 and is based in South San Francisco, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials